{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:46:29Z","timestamp":1782956789599,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12962-y","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:04:11Z","timestamp":1777989851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating dolutegravir into the national Tanzanian formulary: treatment uptake and virologic outcomes from a longitudinal study"],"prefix":"10.1186","volume":"26","author":[{"given":"Joan","family":"Rugemalila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ponsian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chimwege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn D.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"12962_CR1","volume-title":"WHO recommends dolutegravir as preferred HIV treatment option in all populations","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Geneva: World Health Organization; 2019."},{"issue":"10","key":"12962_CR2","doi-asserted-by":"publisher","first-page":"e0000826","DOI":"10.1371\/journal.pgph.0000826","volume":"2","author":"E Ngoufack Jagni Semengue","year":"2022","unstructured":"Ngoufack Jagni Semengue E, Santoro MM, Ndze VN, Ka\u2019e AC, Yagai B, Nka AD, et al. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. PLOS Glob Public Health. 2022;2(10):e0000826.","journal-title":"PLOS Glob Public Health"},{"issue":"7","key":"12962_CR3","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","volume":"5","author":"J Dorward","year":"2018","unstructured":"Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5(7):e400\u20134.","journal-title":"Lancet HIV"},{"issue":"1","key":"12962_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41598-023-51144-7","volume":"14","author":"A Fimbo","year":"2024","unstructured":"Fimbo A, Mwalwisi YH, Mwamwitwa K, Matiko D, Mfinanga E, Lyimo J, et al. Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania. Sci Rep. 2024;14(1):615.","journal-title":"Sci Rep"},{"issue":"11","key":"12962_CR5","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","volume":"74","author":"SY Rhee","year":"2019","unstructured":"Rhee SY, Grant PM, Tzou PL, Barrow G, Harrigan PR, Ioannidis JPA, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019;74(11):3135\u201349.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"12962_CR6","doi-asserted-by":"publisher","first-page":"20493","DOI":"10.1038\/s41598-023-47795-1","volume":"13","author":"GM Bwire","year":"2023","unstructured":"Bwire GM, Aiko BG, Mosha IH, Kilapilo MS, Mangara A, Kazonda P, et al. High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam. Sci Rep. 2023;13(1):20493.","journal-title":"Sci Rep"},{"issue":"7","key":"12962_CR7","doi-asserted-by":"publisher","first-page":"ofad321","DOI":"10.1093\/ofid\/ofad321","volume":"10","author":"AJ Ntamatungiro","year":"2023","unstructured":"Ntamatungiro AJ, Eichenberger A, Okuma J, Vanobberghen F, Ndege R, Kimera N, et al. Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania. Open Forum Infect Dis. 2023;10(7):ofad321.","journal-title":"Open Forum Infect Dis"},{"key":"12962_CR8","doi-asserted-by":"crossref","unstructured":"Kamori D, Barabona G. Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment? Front Virol. 2023;3\u20132023.","DOI":"10.3389\/fviro.2023.1253661"},{"issue":"1","key":"12962_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1186\/s12913-020-05580-0","volume":"20","author":"Y Alhassan","year":"2020","unstructured":"Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, et al. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. BMC Health Serv Res. 2020;20(1):705.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"12962_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12905-023-02630-7","volume":"23","author":"JC Chapola","year":"2023","unstructured":"Chapola JC, Lee F, Bula A, Rosenberg NE, Tseka J, Chagomerana M, et al. Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV. BMC Womens Health. 2023;23(1):478.","journal-title":"BMC Womens Health"},{"issue":"5","key":"12962_CR11","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","volume":"10","author":"J Dorward","year":"2023","unstructured":"Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, et al. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10(5):e284\u201394.","journal-title":"Lancet HIV"},{"issue":"1","key":"12962_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/M21-3037","volume":"175","author":"ML Romo","year":"2022","unstructured":"Romo ML, Patel RC, Edwards JK, Humphrey JM, Musick BS, Bernard C, et al. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity: An Observational Study. Ann Intern Med. 2022;175(1):84\u201394.","journal-title":"Ann Intern Med"},{"key":"12962_CR13","doi-asserted-by":"crossref","unstructured":"Asare K, Lewis L, van der Molen J, Sookrajh Y, Khubone T, Moodley P et al. Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa. Open Forum Infect Dis. 2023;10(12).","DOI":"10.1093\/ofid\/ofad583"},{"issue":"8","key":"12962_CR14","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","volume":"9","author":"B Schramm","year":"2022","unstructured":"Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, et al. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Lancet HIV. 2022;9(8):e544\u201353.","journal-title":"Lancet HIV"},{"issue":"3","key":"12962_CR15","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1093\/infdis\/jiae260","volume":"230","author":"SM McCluskey","year":"2024","unstructured":"McCluskey SM, Muyindike WR, Nanfuka V, Omoding D, Komukama N, Barigye IT, et al. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results. J Infect Dis. 2024;230(3):e622\u201330.","journal-title":"J Infect Dis"},{"key":"12962_CR16","doi-asserted-by":"crossref","unstructured":"Semengue ENJ, Fokam J, Etame NK, Molimbou E, Chenwi CA, Takou D, et al. Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-LINE ART in cameroon: an evidence of a successful transition model. Viruses. 2022;15(1).","DOI":"10.3390\/v15010018"},{"issue":"1","key":"12962_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12981-024-00662-z","volume":"21","author":"RT Majula","year":"2024","unstructured":"Majula RT, Mweya CN. Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania. AIDS Res Therapy. 2024;21(1):98.","journal-title":"AIDS Res Therapy"},{"issue":"3","key":"12962_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","volume":"91","author":"E Allahna","year":"2022","unstructured":"Allahna E, Nicole D, Neha S, Hannah K, Jonah M, John O, et al. Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study. J Acquir Immune Defic Syndr. 2022;91(3):285\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"12962_CR19","doi-asserted-by":"publisher","first-page":"e0307003","DOI":"10.1371\/journal.pone.0307003","volume":"19","author":"D Kamori","year":"2024","unstructured":"Kamori D, Barabona G, Maokola W, Rugemalila J, Mahiti M, Mizinduko M, et al. HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania. PLoS ONE. 2024;19(8):e0307003.","journal-title":"PLoS ONE"},{"issue":"1","key":"12962_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12981-025-00780-2","volume":"22","author":"AA Maghembe","year":"2025","unstructured":"Maghembe AA, Boer MS-d, Mtoro MJ, Mahande MJ. Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis. AIDS Res Therapy. 2025;22(1):82.","journal-title":"AIDS Res Therapy"},{"issue":"6","key":"12962_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jpids\/piad040","volume":"12","author":"SA Khamadi","year":"2023","unstructured":"Khamadi SA, Bahemana E, Dear N, Mavere C, George F, Kapene R, et al. Factors Associated With Viral Suppression and Drug Resistance in Children and Adolescents Living With HIV in Care and Treatment Programs in Southern Tanzania. J Pediatr Infect Dis Soc. 2023;12(6):353\u201363.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"12962_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12981-024-00622-7","volume":"21","author":"SE Mushy","year":"2024","unstructured":"Mushy SE, Mtisi E, Mkawe S, Mboggo E, Ndega J, Yahya-Malima KI, et al. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania. AIDS Res Ther. 2024;21(1):35.","journal-title":"AIDS Res Ther"},{"issue":"9","key":"12962_CR23","doi-asserted-by":"publisher","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","volume":"16","author":"C Waitt","year":"2019","unstructured":"Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895.","journal-title":"PLoS Med"},{"issue":"1","key":"12962_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-023-00572-6","volume":"20","author":"S SeyedAlinaghi","year":"2023","unstructured":"SeyedAlinaghi S, Afsahi AM, Moradi A, Parmoon Z, Habibi P, Mirzapour P, et al. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Ther. 2023;20(1):74.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"12962_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12981-021-00352-0","volume":"18","author":"C-P Rolle","year":"2021","unstructured":"Rolle C-P, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. AIDS Res Therapy. 2021;18(1):26.","journal-title":"AIDS Res Therapy"},{"key":"12962_CR26","doi-asserted-by":"crossref","unstructured":"KamoriD, Barabona G, Rugemalila J, Maokola W, Masoud SS, Mizinduko M, et al. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey. J Antimicrob Chemother. 2023;78 (3):779-87. https:\/\/pubmed.ncbi.nlm.nih.gov\/36680436\/.","DOI":"10.1093\/jac\/dkad010"},{"key":"12962_CR27","doi-asserted-by":"crossref","unstructured":"LoosliT, Moore CB, Buzaalirwa L, Byakwaga H, \u00c7elika\u011f \u0130, Chimbetete C, et al. Drug resistance in people with viremia on dolutegravir-based antiretroviral therapy in Sub-Saharan Africa: The DTG RESIST Study. Clin Infect Dis. 2025;81(4):e128-e131. https:\/\/pubmed.ncbi.nlm.nih.gov\/40391923\/.","DOI":"10.1093\/cid\/ciaf204"},{"issue":"12","key":"12962_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","volume":"32","author":"M Vitoria","year":"2018","unstructured":"Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? Aids. 2018;32(12):1551\u201361.","journal-title":"Aids"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12962-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:23:06Z","timestamp":1782955386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12962-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12962"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12962-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to conduct this study was received from the Muhimbili National Hospital Research Ethics Committee (MNH) and approved to perform data extraction of routinely collected participant-level data. A waiver of consent for participation in the study was granted by the ethics committee given that investigators utilized de-identified routine collected data with no contacting participants. This study was conducted in compliance with the ethical principles in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1203"}}